Bladder-Cancer Trial Meets Main Goal, Sending CG Oncology Stock Up 11%
The company expects its broadened FDA application by the end of March 2027, following results showing a 68% reduction in recurrence risk compared with surveillance.
CG Oncology, which develops an experimental bladder-cancer treatment, soared about 11% to $82.46 in Monday trading, as of 9:46 AM ET, adding $720 million in market value. The shares reached a new 52-week high after cretostimogene met the main goal of a late-stage trial, according to the company's SEC filing Monday.
Lower recurrence after tumor removal
Patients receiving cretostimogene had a 68% lower risk of recurrence than those monitored through surveillance after tumor removal. The randomized study enrolled 367 patients.
Treatment-related severe side effects and withdrawals attributable to treatment were both absent from researchers' records during follow-up lasting a median of 17 months. The results support the company's planned pursuit of broader FDA approval.
Cretostimogene is delivered into the bladder and is designed to attack cancer cells while activating an immune response against tumors. CG Oncology's program targets high-risk and intermediate-risk disease that has not spread into the bladder's muscle wall, studying the treatment alone and with other cancer medicines in mid-stage and late-stage trials. The company relies on third-party manufacturers.
A broader application timetable
CG Oncology expects to complete its broadened initial FDA application by the end of March 2027. It expects a second application in the second quarter of 2027.
Its November 6 business update had put completion of the initial application in the fourth quarter of 2026. That application targeted patients whose cancer had not responded to BCG treatment.
The company also expects December results tracking patients for 12 months in the CORE-008 Cohort CX and BOND-003 Cohort P studies. Arthur Kuan, CG Oncology's chairman, president and chief executive officer, said in the November 6 update, “we expect to have 12-month data from both CORE-008 Cohort CX and BOND-003 Cohort P in December”.
A rally backed by cash
Monday's rise put the stock on pace for its second gain of 10% or more this month. CG Oncology's market value stood at about $7.4 billion in Monday trading.
Shares were up 79% for the year at Friday's close, compared with 11% for the S&P 500. The stock had gained 19% over the previous month.
CG Oncology reported third-quarter revenue of $1.6 million and a net loss of $56.9 million, versus a $43.8 million loss a year earlier. Loss per share widened to $0.64 from $0.57.
Research spending rose to $39.2 million from $27.9 million, which the company attributed primarily to clinical-trial and manufacturing-related costs and higher staff pay. Administrative spending fell to $23.0 million from $23.3 million.
Cash, cash equivalents and marketable securities totaled $984.5 million on September 30, compared with $1.0 billion on June 30. Management expects those funds to support operations through 2029.
The next clinical readouts are expected in December; the broadened initial FDA application is now expected by the end of March 2027.
Sources
- CG Oncology’s bladder cancer treatment beats expectations in Phase 3 — endpoints.news
- EX-99.1 — sec.gov
- PIVOT-006 Phase 3 Registrational Trial Demonstrates — globenewswire.com
- The company's filing (CG Oncology) — SEC filing
- CG Oncology — Form 10-Q for the quarter ended 2026-09-30 (quarterly results) — SEC EDGAR
- CG Oncology — earnings release (Form 8-K, Item 2.02), filed 2026-11-06 — SEC EDGAR